Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
Sci Transl Med. 2013 Oct 23;5(208):208fs38. doi: 10.1126/scitranslmed.3007622.
The SS1P immunotoxin is combined with immunomodulatory therapy in order to improve its efficacy in human mesothelioma (Hassan et al., this issue).
SS1P 免疫毒素与免疫调节疗法相结合，以提高其在人类间皮瘤中的疗效（Hassan 等人，本期）。
